Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 2, 2002 - Issue 5
Submit an article Journal homepage
15
Views
0
CrossRef citations to date
0
Altmetric
Special Report

Outcomes of dalteparin use following total knee arthroplasty: a retrospective analysis

Philip C Comp Veterans Administration Medical Center, Oklahoma City, OK, USA. [email protected]
,
Jeffrey D Miller Medical Research International, Waltham, MA, USA. [email protected]
,
Kevin W Mayo Global Pricing, Reimbursement and Market Access, Pharmacia Corp., Peapack, NJ, USA. [email protected]
,
Samuel Wagner Pharmacia Corp., Peapack, NJ, USA. [email protected]
&
Mason W Russell Medical Research International, Waltham, MA, USA. [email protected]
Pages 427-434 | Published online: 09 Jan 2014

References

  • Hirsh J, Dalen J, Guyatt G, American College of Chest Physicians. The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians. Chest 119(1 Suppl.), 1S-2S (2001).
  • Leclerc JR. DVT prophylaxis- pharmacologic prophylaxis and treatment of venous thromboembolism after lower extremity arthroplasty. Medscape Orthopaedics & Sports Medicine efournal [serial available online at www.medscape.com/viewarticle/408489 (accessed July 3, 2002)]. 2(6), (1998).
  • Bergqvist D. Prolonged prophylaxis in postoperative medicine. Semin. Thmmb. Hemost. 23(2), 149–154 (1997).
  • Paiement GD, Mendelsohn C. The risk of venous thromboembolism in the orthopedic patient: epidemiological and physiological data. Chihopeclics20(Suppl.), 7–9 (1997).
  • Ciccone WJ, Pellegrini VD. Deep venous thrombosis after total knee arthroplasty.Comp. Orthop. 11(4), 11–15, 27 (1996).
  • Hull R, Raskob G, Pineo G et al A comparison of sc. low-molecular weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl. Med. 329(19), 1370–1376 (1993).
  • Hirsh J. Prevention of venous thrombosis in patients undergoing major orthopaedic surgical procedures. Acta Chit: Land. Suppl. 556,30–35 (1990).
  • Nurmohamed MT, Rosendaal FR, Buller HR et al Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 340(8812), 152–156 (1992).
  • Bergqvist D, Benoni G, Bjorge11 0 eta]. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl. I Med 335(10), 696–700 (1996).
  • Lassen MR, Borris LC, Anderson BS eta]. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty — the Danish Prolonged Prophylaxis (DaPP) Study. Thromb. Res. 89(6), 281–287 (1998).
  • Wade WE, Bradley CM, Kotzan JA et al Formulary management of low molecular weight heparins. PharmacoEconomics17(1), 1–12 (2000).
  • •Good review of the clinical uses and formulary considerations for LMWHs, with an assessment of selected LMWH economic studies.
  • Davidson BL. Controversies in pulmonary embolism and deep venous thrombosis. Am. Fam. Physician 60,1969–1980 (1999).
  • Iobst CA, Friedman RJ. The role of low molecular weight heparin in total knee arthroplasty. Am J Knee Surg 12 (1), 55–60 (1999).
  • Planes A, Vochelle N, Fafola M. Venous thromboembolic prophylaxis in orthopedic surgery: knee surgery. Semin. Thromb. Hemost 25 (Suppl. 3), 73–77 (1999).
  • Zimlich RII, Fulbright BM, Friedman RJ. Current status of anticoagulation therapy after total hip and total knee arthroplasty. Am. Acad. Orthop. Surg 4(2), 54–62 (1996).
  • Rydberg EJ, Westfall JM, Nicholas RA. Low-molecular-weight heparin in preventing and treating DVT Am. Fain. Physician 59,1607–1612 (1999).
  • Anderson DR, O'Brien BJ. Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism. PharmacoEconomics 12(1), 17–29 (1997).
  • Heaton D, Pearce M. Low molecular weight versus unfractionated heparin: a clinical and economic appraisal. PhamacoEconomics8(2), 91–99 (1995).
  • Paiement GD, Wessinger SJ, Harris WH. Cost-effectiveness of prophylaxis in total hip replacement. Ain. I Surg 161(4), 519–524 (1991).
  • Colwell CW Jr, Spiro TE, Trowbridge AA et al Use of enoxaparin, a low-molecular-weight heparin and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Bone Joint Surg. Am 76(1), 3–14 (1994).
  • O'Brien BJ, Anderson DR, Goeree R. Cost- effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. CM4J150 (7), 1083–1090 (1994).
  • Menzin J, Colditz GA, Regan MM et al Cost-effectiveness of enoxaparin vs. low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Awh. Intern. Med 155(7), 757–764 (1995).
  • Hull RD, Raskob GE, Pineo GF et al Subcutaneous low-molecular-weight heparin vs. warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Awh. Intern. Med. 157(3), 298–303 (1997).
  • Hull RD, Pineo GF, Raskob GE. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects. Haemostasis28\(Suppl. 3), 8–16 (1998).
  • Garcia-Zozaya I. Warfarin vs. enoxaparin for deep venous thrombosis prophylaxis after total hip & total knee arthroplasty: a cost comparison. J. Ky Med Assoc 96(4), 143–148 (1998).
  • Fitzgerald RII Jr, Spiro TE, Trowbridge AA et al Enoxaparin Clinical Trial Group. Prevention of venous thromboembolic disease following primary total knee arthroplasty. a randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg. Am. 83-A(6), 900–906 (2001).
  • American Medical Rehabilitation Providers Association. Letter to Ms. Michael McMullan, Acting Administrator, Healthcare Financing Administration, regarding `HCFA -1069-P, Proposed Rule for the Medicare Prospective Payment System for In-patient Rehabilitation Facilities (65 ER. 66303), November 3, 2000.' January 29,2001. Available online at www.amrpa.orgianalysis-08.htm (accessed July 3,2002).
  • Krotenberg R, Adler U, Pomeranz B et al A retrospective analysis of outcomes and costs of dalteparin versus enoxaparin as prophylaxis for deep-vein thrombosis in patients undergoing in-patient rehabilitation following total hip or knee arthroplasty. Am. J Phys. Med. Rehabil 80(12), 889–895 (2001).
  • ••The methods and results of this study are similar to those presented here.
  • Medical Economics Company Inc. Physicians' Desk Reference 2000 Montvale, NJ, USA (2000).
  • Hunter JB, Frostick SR Dalteparin (Fragmin) for the prevention of early mortality after orthopedic surgery. Thmmb. I-Lemost. 73,977 (1995).
  • Haas S, Mosca P, Windsor RE eta]. Fragmin versus warfarin for prevention of deep vein thrombosis after total knee arthroplasty-a randomized double-blind study. Paper No. 346. Am. Acad. Cfrthop. Surg (1997).
  • Pharmacia Corp. (Patel I, Sylvester C, Schoenfelder J et al). A double-blind randomized study evaluating the thromboprophylactic efficacy of Fragmin versus warfarin in total knee replacement: report of study CTN 91–138. Document No. 9610542.
  • Niskanen RO, Korkala OL, Haapala J et al Drainage is of no use in primary uncomplicated cemented hip and knee arthroplasty for osteoarthritis: a prospective randomized study. J. Arthroplasty 15 (5), 567–569 (2000).
  • Medical Economics Company Inc. 2000 Drug- Topics° RED BOOK°. Montvale, NJ, USA (2000).
  • Schafermeyer KW Schondelmeyer SW, Thomas J, Proctor IKA. An analysis of the cost of dispensing third-party prescriptions in chain pharmacies. J Res. Pharrn. Econ. 4(3), 3–24 (1992).
  • Geerts WH, Heit JA, Clagett GP et al Prevention of venous thromboembolism. Chest 119(1 Suppl.), 132S-175S (2001).
  • LeClerc JR, Gent M, Hirsh J et al The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1984 patients. Chest 114 (2 Suppl.), 115S-118S (1998).
  • Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Arch. Intern. Med. 158(8), 873–878 (1998).
  • Department of Health, and Human Services, Centers for Medicare and Medicare Services, 'Medicare Program; Prospective Payment System for In-patient Rehabilitation Facilities: Final Rule,' Federal Register; vol. 56, no. 152, August 7,2001.
  • Planes A, Vochelle N, Darmon JY et al Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 348(9022), 224–228 (1996).
  • Seagroatt V, Tan HS, Goldacre M et al Elective total hip replacement: incidence, emergency readmission rate and postoperative mortality. BE Med. J 303(6815), 1431–1435 (1991).

Websites

  • www.hcfa.gov/stats/pufiles.htm (accessed August 15, 2002).
  • www.hcfa.gov/medicare/irfpps.htm (accessed July 3, 2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.